π Congratulations to our collaborators on their recent publications
March 26, 2026
We are delighted to congratulate
EpiEndo Pharmaceuticals and the Institute of Pharmaceutical Science,
King's College London
on the publication of two exciting studies exploring the therapeutic potential of EP395:
π “The Effect of the Novel Macrolide Glasmacinal (EP395) on Allergen-Induced Eosinophil Infiltration into the Lung” published in "Lung"
π “Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation” published in "Pulmonary Pharmacology & Therapeutics"
These studies provide valuable insights into the role of EP395 in modulating inflammatory responses in respiratory disease, supporting its potential as a novel therapeutic approach.
At
Pharmidex, we are proud to have contributed to this work through our Respiratory Department, supporting the in vivo studies and helping advance these important findings.
We look forward to continuing our collaboration and supporting innovative programmes in respiratory drug discovery and development.
#RespiratoryResearch #DrugDiscovery #Inflammation #Preclinical #Collaboration #Pharmidex
πβοΈβοΈ Congratulations to our Pharmidex team members who took part in the St Albans Summer Solstice 10K #BeatTheSunset ! It was great to see colleagues enjoying a fantastic summer evening while supporting their physical and mental wellbeing. At Pharmidex , we believe health extends beyond the laboratory and activities like these are a great way to stay active, connect with colleagues and have fun. Well done to everyone who took part and represented Pharmidex so positively!
A big thank you to our interns from City St George’s, University of London and heir fantastic contribution to Pharmidex over the past few months. They have supported scientific projects across the business, developed valuable technical skills and gained hands-on experience within a CRO environment. Their contribution has extended beyond the laboratory, helping with our website, marketing materials, conference preparation and business development activities. Science drives success, but communicating that science effectively is just as important. Our interns have helped us do both. Thank you for your hard work, enthusiasm, and dedication. We wish you every success in the next stage of your careers.
On 18 June, our COO, Ash Alavijeh , will join an industry panel discussing: "What are the advantages and disadvantages of working with UK-based Discovery CROs?" The session will explore the value of UK CROs in supporting innovation, protecting IP, accessing scientific expertise and accelerating drug discovery programmes. π
18 June 2025 π Cambridge π Panel Session: 12:20–12:45 We look forward to connecting with colleagues, collaborators, and innovators from across the life sciences community.
